Christopher G Schwarz

List of Publications by Year
in descending order

157 papers	6,620 citations	57758 44 h-index	82547 72 g-index
160 all docs	160 docs citations	160 times ranked	7356 citing authors

#	Article	IF	Citations
1	*APOE* ε4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 784-796.	0.8	7
2	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Communications, 2022, 4, fcac017.	3.3	12
3	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	3.3	15
4	Left–Right Intensity Asymmetries Vary Depending on Scanner Model for FLAIR and T 1 Weighted MRI Images. Journal of Magnetic Resonance Imaging, 2022, , .	3.4	3
5	A novel computer adaptive word list memory test optimized for remote assessment: Psychometric properties and associations with neurodegenerative biomarkers in older women without dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12299.	2.4	8
6	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. NeuroImage: Clinical, 2022, 34, 102999.	2.7	11
7	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	3.9	11
8	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging. NeuroImage, 2022, 251, 119020.	4.2	9
9	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. Neurology, 2022, 98, .	1.1	12
10	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. Brain Communications, 2022, 4, .	3.3	5
11	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	11.6	52
12	CSF phosphorylated tau as an indicator of subsequent tau accumulation. Neurobiology of Aging, 2022, 117, 189-200.	3.1	4
13	Face recognition from research brain PET: An unexpected PET problem. NeuroImage, 2022, 258, 119357.	4.2	6
14	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. Cerebral Cortex, 2021, 31, 1693-1706.	2.9	44
15	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	4.2	63
16	Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	9.0	27
17	Phonological Errors in Posterior Cortical Atrophy. Dementia and Geriatric Cognitive Disorders, 2021, 50, 195-203.	1.5	8
18	β-Amyloid PET and [123] I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.1	13

#	Article	IF	Citations
19	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	2.7	27
20	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. Frontiers in Neurology, 2021, 12, 615024.	2.4	5
21	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. Journal of Neurology, 2021, 268, 3409-3420.	3.6	12
22	Uses of Human MR and PET Imaging in Research of Neurodegenerative Brain Diseases. Neurotherapeutics, 2021, 18, 661-672.	4.4	9
23	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. Brain Communications, 2021, 3, fcab106.	3.3	38
24	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	2.0	13
25	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. NeuroImage, 2021, 231, 117845.	4.2	38
26	CSF dynamics as a predictor of cognitive progression. NeuroImage, 2021, 232, 117899.	4.2	3
27	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	7.6	26
28	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. Nature Communications, 2021, 12, 3452.	12.8	34
29	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2669-2675.	3.9	4
30	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	4.2	24
31	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	3.1	18
32	Relationships between Î²-amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440.	4.2	15
33	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. Neurobiology of Aging, 2021, 108, 90-98.	3.1	11
34	In vivo imaging and autoradiography in a case of autopsy-confirmed Pick disease. Neurology: Clinical Practice, 2021, 11, 10.1212/CPJ.0000000000000755.	1.6	4
35	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. NeuroImage: Clinical, 2021, 32, 102850.	2.7	13
36	Changes in Ventricular and Cortical Volumes following Shunt Placement in Patients with Idiopathic Normal Pressure Hydrocephalus. American Journal of Neuroradiology, 2021, , .	2.4	2

#	ARTICLE	IF	CITATIONS
37	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. Journal of Alzheimer's Disease, 2021, , 1-6.	2.6	1
38	White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12269.	2.4	1
39	Optimizing software methods for measuring flortaucipir SUVR change over time. Alzheimer's and Dementia, 2021, 17, .	0.8	0
40	Dementia with Lewy bodies subtypes identified by cluster analysis on structural MRI. Alzheimer's and Dementia, 2021, 17, .	0.8	0
41	Pattern of regional white matter hyperintensity volume in mild cognitive impairment subtypes and associations with decline in daily functioning. Neurobiology of Aging, 2020, 86, 134-142.	3.1	30
42	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.8	113
43	Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech. Cortex, 2020, 124, 33-43.	2.4	5
44	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.1	65
45	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.1	62
46	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	7.6	74
47	Longitudinal Amyloid-Î² PET in Atypical Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	2.6	7
48	Sensitivityâ€"Specificity of Tau and Amyloid Î² Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022.	5.3	32
49	Popular MRI deâ€facing software does not sufficiently protect participants from reâ€identification via face recognition. Alzheimer's and Dementia, 2020, 16, e045157.	0.8	1
50	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2020, 16, 1013-1022.	0.8	20
51	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. Mayo Clinic Proceedings, 2020, 95, 1195-1205.	3.0	30
52	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.1	27
53	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	7.6	51
54	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. Neurology, 2020, 94, e1793-e1802.	1.1	28

#	ARTICLE	IF	CITATIONS
55	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. Neurobiology of Aging, 2020, 92, 135-140.	3.1	3
56	Editorial for "Improving Spatial Normalization of Brain Diffusion MRI to Measure Longitudinal Changes of Tissue Microstructure in the Cortex and White Matter" Journal of Magnetic Resonance Imaging, 2020, 52, 776-777.	3.4	0
57	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. NeuroImage: Clinical, 2020, 25, 102152.	2.7	46
58	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567.	5.3	17
59	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	3.7	17
60	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. Human Brain Mapping, 2019, 40, 1618-1631.	3.6	53
61	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. Brain and Language, 2019, 197, 104676.	1.6	29
62	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer's Association Research Framework. JAMA Neurology, 2019, 76, 1174.	9.0	182
63	Multimodal neuroimaging relationships in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 56-61.	2.2	19
64	Identification of Anonymous MRI Research Participants with Face-Recognition Software. New England Journal of Medicine, 2019, 381, 1684-1686.	27.0	124
65	The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	7.6	129
66	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. Stroke, 2019, 50, 3037-3044.	2.0	39
67	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	7.6	37
68	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	3.1	14
69	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. Brain, 2019, 142, 2466-2482.	7.6	33
70	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	7.4	223
71	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. Movement Disorders Clinical Practice, 2019, 6, 452-461.	1.5	26
72	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.1	62

#	Article	IF	Citations
73	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	7.6	126
74	Investigation of white matter PiB uptake as a marker of white matter integrity. Annals of Clinical and Translational Neurology, 2019, 6, 678-688.	3.7	18
75	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101823.	2.7	54
76	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain, 2019, 142, 1134-1147.	7.6	72
77	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 675-685.	0.8	36
78	Neural correlates of domain-specific cognitive decline. Neurology, 2019, 92, e1051-e1063.	1.1	12
79	Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	7.6	68
80	IC-P-127: VARIABILITY IN MRI AND PET MEASUREMENTS INTRODUCED BY CHANGE IN MRI VENDOR. Alzheimer's and Dementia, 2019, 15, P104.	0.8	3
81	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.1	19
82	Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	5.9	22
83	MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 105-113.	3.9	33
84	The influence of β-amyloid on [^{18} F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.1	10
85	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurology, 2019, 76, 95.	9.0	69
86	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. Journal of Alzheimer's Disease, 2019, 67, 181-195.	2.6	48
87	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. NeuroImage: Clinical, 2019, 21, 101605.	2.7	29
88	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. Frontiers in Aging Neuroscience, 2019, 11, 355.	3.4	25
89	White Matter Reference Region in PET Studies of ^{11}C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-β Deposition. Journal of Nuclear Medicine, 2018, 59, 1583-1589.	5.0	37
90	Diffusion Specific Segmentation: Skull Stripping with Diffusion MRI Data Alone. Mathematics and Visualization, 2018, , 67-80.	0.6	1

#	Article	IF	Citations
91	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 1713-1724.	2.6	45
92	Elevated medial temporal lobe and pervasive brain tau–PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	2.4	19
93	[18F]AV–1451 tau–PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	5.3	73
94	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. Cortex, 2018, 99, 358-374.	2.4	42
95	In vivo 18 F-AV-1451 tau PET signal in *MAPT* mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.1	60
96	[18F]AV–1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	5.3	67
97	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. Brain, 2018, 141, 302-317.	7.6	42
98	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain, 2018, 141, 271-287.	7.6	218
99	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1244-1250.	3.6	30
100	Longitudinal tau PET in ageing and Alzheimer's disease. Brain, 2018, 141, 1517-1528.	7.6	309
101	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	7.6	67
102	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	3.0	34
103	IC–P–189: METHODS TO IMPROVE SPM12 TISSUE SEGMENTATIONS OF OLDER ADULT BRAINS. Alzheimer's and Dementia, 2018, 14, P157.	0.8	1
104	P2–334: THE INFLUENCE OF BETA–AMYLOID ON THE PROGRESSION OF PROGRESSIVE APRAXIA OF SPEECH. Alzheimer's and Dementia, 2018, 14, P810.	0.8	1
105	P3–382: METHODS TO IMPROVE SPM12 TISSUE SEGMENTATIONS OF OLDER ADULT BRAINS. Alzheimer's and Dementia, 2018, 14, P1240.	0.8	2
106	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	5.3	49
107	Medical Image Synthesis for Data Augmentation and Anonymization Using Generative Adversarial Networks. Lecture Notes in Computer Science, 2018, , 1-11.	1.3	265
108	Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech. European Journal of Neurology, 2018, 25, 1352-1357.	3.3	12

#	Article	IF	Citations
109	Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain and Language, 2018, 184, 54-65.	1.6	106
110	Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. Scientific Reports, 2018, 8, 7421.	3.3	9
111	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. Neurocase, 2018, 24, 111-120.	0.6	25
112	White matter hyperintensities correlate to cognition and fiber tract integrity in older adults with HIV. Journal of NeuroVirology, 2017, 23, 422-429.	2.1	55
113	The value of resting-state functional MRI in subacute ischemic stroke: comparison with dynamic susceptibility contrast-enhanced perfusion MRI. Scientific Reports, 2017, 7, 41586.	3.3	33
114	Contributions of imprecision in <scp>PET</scp>â€‹<scp>MRI</scp> rigid registration to imprecision in amyloid <scp>PET</scp><scp>SUVR</scp> measurements. Human Brain Mapping, 2017, 38, 3323-3336.	3.6	26
115	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	3.1	158
116	Tauâ€‹PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 21-30.	2.4	86
117	[ICâ€‹Pâ€‹021]: INVESTIGATION OF PITTSBURGH COMPOUNDâ€‹B BINDING IN WHITE MATTER HYPERINTENSITIES. Alzheimer's and Dementia, 2017, 13, P23.	0.8	0
118	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	2.2	7
119	[¹⁸F]AVâ€‹1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 2017, 32, 124-133.	3.9	136
120	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.8	41
121	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. NeuroImage, 2017, 144, 113-127.	4.2	59
122	[P2â€"415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2017, 13, P792.	0.8	33
123	[P3â€"343]: INVESTIGATION OF PITTSBURGH COMPOUNDâ€‹B BINDING IN WHITE MATTER HYPERINTENSITIES. Alzheimer's and Dementia, 2017, 13, P1085.	0.8	0
124	[ICâ€‹Pâ€‹019]: EFFECTS OF USING A NOVEL LONGITUDINAL PROCESSING PIPELINE FOR MEASURING CHANGE OVER TIME IN PIBâ€‹PET. Alzheimer's and Dementia, 2017, 13, P21.	0.8	0
125	[ICâ€‹Pâ€‹072]: AUTOMATED MEASUREMENT OF SULCAL CSF SPACES TO DETECT IMAGING PHENOTYPES OF DISPROPORTIONATELY ENLARGED SUBARACHNOID HYDROCEPHALUS. Alzheimer's and Dementia, 2017, 13, P59.	0.8	0
126	[ICâ€‹Pâ€‹122]: THE MAYO CLINIC ADULT LIFE SPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFE SPAN. Alzheimer's and Dementia, 2017, 13, P93.	0.8	22

#	Article	IF	Citations
127	[P1–380]: AUTOMATED MEASURMENT OF SULCAL CSF SPACES TO DETECT IMAGING PHENOTYPES OF DISPROPORTIONATELY ENLARGED SUBARACHNOID HYDROCEPHALUS. Alzheimer's and Dementia, 2017, 13, P410.	0.8	0
128	[P1–446]: EFFECTS OF USING A NOVEL LONGITUDINAL PROCESSING PIPELINE FOR MEASURING CHANGE OVER TIME IN PIB–PET. Alzheimer's and Dementia, 2017, 13, P455.	0.8	1
129	[1] H-MRS metabolites and rate of β-amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.1	18
130	Comparison of [18 F]Flutemetamol and [11 C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. NeuroImage: Clinical, 2017, 16, 295-302.	2.7	30
131	Disrupted functional connectivity between perirhinal and parahippocampal cortices with hippocampal subfields in patients with mild cognitive impairment and Alzheimer's disease. Oncotarget, 2017, 8, 99112-99124.	1.8	5
132	An MRI–Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. Journal of Neuroimaging, 2016, 26, 264-268.	2.0	3
133	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. NeuroImage: Clinical, 2016, 11, 802-812.	2.7	249
134	P4-092: Optimizing PiB-PET change-over-time measurement by analysis of longitudinal reliability, plausibility, and separability. , 2015, 11, P808-P809.		0
135	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. Journal of Alzheimer's Disease, 2015, 49, 633-643.	2.6	27
136	IC-04-04: Optimizing PiB-PET change-over-time measurement by analysis of longitudinal reliability, plausibility, and separability. , 2015, 11, P11-P12.		0
137	Apolipoprotein ε4 Is Associated with Lower Brain Volume in Cognitively Normal Chinese but Not White Older Adults. PLoS ONE, 2015, 10, e0118338.	2.5	12
138	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain and Language, 2015, 142, 45-53.	1.6	49
139	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. Cortex, 2015, 69, 220-236.	2.4	133
140	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017.	3.1	35
141	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. JAMA Neurology, 2014, 71, 1547.	9.0	57
142	Characterizing Topological Patterns in Amnestic Mild Cognitive Impairment by Quantitative Water Diffusivity. Journal of Alzheimer's Disease, 2014, 43, 687-697.	2.6	10
143	The evolution of primary progressive apraxia of speech. Brain, 2014, 137, 2783-2795.	7.6	134
144	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. NeuroImage, 2014, 94, 65-78.	4.2	155

#	Article	IF	Citations
145	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism and Related Disorders, 2014, 20, 493-498.	2.2	49
146	White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment. Alzheimer's and Dementia, 2013, 9, S124-31.	0.8	61
147	Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. Neurobiology of Aging, 2013, 34, 1996-2002.	3.1	66
148	Dissociable Effects of Alzheimer Disease and White Matter Hyperintensities on Brain Metabolism. JAMA Neurology, 2013, 70, 1039.	9.0	54
149	Effects of T2-weighted MRI based cranial volume measurements on studies of the aging brain. Proceedings of SPIE, 2013, 8669, .	0.8	4
150	Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage.. Psychology and Aging, 2013, 28, 191-201.	1.6	32
151	Most edges in Markov random fields for white matter hyperintensity segmentation are worthless. , 2012, 2012, 2684-7.		1
152	Episodic memory function is associated with multiple measures of white matter integrity in cognitive aging. Frontiers in Human Neuroscience, 2012, 6, 56.	2.0	100
153	Impact of Markov Random Field optimizer on MRI-based tissue segmentation in the aging brain. , 2011, 2011, 7812-5.		0
154	Longitudinal Changes in White Matter Disease and Cognition in the First Year of the Alzheimer Disease Neuroimaging Initiative. Archives of Neurology, 2010, 67, 1370.	4.5	216
155	Fully-Automated White Matter Hyperintensity Detection with Anatomical Prior Knowledge and without FLAIR. Lecture Notes in Computer Science, 2009, 21, 239-251.	1.3	84
156	The Camera-Driven Interactive Table. , 2007, , .		2
157	Segment-Based Hand Pose Estimation. , 0, , .		10